Today: 21 May 2026
Browse Category

NASDAQ:CHR 5 November 2025 - 9 December 2025

Cheer Holding (CHR) Stock: Buyout Bids, Nasdaq Delisting Risk and Wild Penny-Stock Volatility as of December 9, 2025

Cheer Holding (CHR) Stock: Buyout Bids, Nasdaq Delisting Risk and Wild Penny-Stock Volatility as of December 9, 2025

Cheer Holding (NASDAQ: CHR) traded at about $0.048 per share on December 9, 2025, down roughly 98% year-to-date. The Beijing-based AI firm faces a Nasdaq delisting process, is considering two preliminary buyout offers at over 10 times its current price, and continues raising capital through dilutive offerings. Market cap estimates range from under $1 million to $5 million.
9 December 2025
Cheer Holding (NASDAQ: CHR) Stock Today: Tiny AI Metaverse Player Weighs Two Takeover Bids as Shares Spike Pre‑Market

Cheer Holding (NASDAQ: CHR) Stock Today: Tiny AI Metaverse Player Weighs Two Takeover Bids as Shares Spike Pre‑Market

Cheer Holding’s board has formed a special committee to review two rival cash buyout offers at $0.56 and $0.52 per Class A share, both far above today’s $0.0477 price. Shares surged over 10% pre-market but remain deep in penny-stock territory after a 65% slide in 10 days. The committee, led by Chairman Bing Zhang, has not made any decision and may hire outside advisers. No deal is assured, the company said.
19 November 2025
····
Cheer Holding (CHR) Stock Skyrockets on Buyout Bids – Inside the AI Innovator’s Rollercoaster Ride

Cheer Holding (CHR) Stock Skyrockets on Buyout Bids – Inside the AI Innovator’s Rollercoaster Ride

Cheer Holding shares jumped nearly 90% to $0.26 on Nov. 5 after the company said it received two preliminary buyout offers. Trading volume soared to 316 million shares, far above the three-month average. The China-based digital media firm, listed on Nasdaq, had a pre-spike market cap of about $1.5 million. CEO Bing Zhang leads the company, which rebranded as Cheer Holding in 2023.
5 November 2025
··

Stock Market Today

  • 3 Middle Eastern Penny Stocks With Market Caps Over US$3M
    May 21, 2026, 12:54 AM EDT. Investors cautious amid geopolitical risks and volatile oil. Three Middle Eastern penny stocks spotlighted for strong financials despite challenges. Airtouch Solar Ltd (market cap ₪15.08M) cut losses 11% annually, with revenue of ₪38.03M but increased net loss of ₪8.12M, maintaining more cash than debt and a 3-year cash runway. Big Tech 50 R&D (market cap ₪10.75M) is pre-revenue, reducing net loss to $2.85M, debt-free with 3+ years cash runway, led by an experienced board. Sonovia Ltd (market cap ₪9.27M) develops anti-bacterial textiles, details limited in the report. These firms show potential in under-the-radar Middle Eastern markets amid uncertain environment.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Go toTop